CZ2003555A3 - 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta - Google Patents

3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta Download PDF

Info

Publication number
CZ2003555A3
CZ2003555A3 CZ2003555A CZ2003555A CZ2003555A3 CZ 2003555 A3 CZ2003555 A3 CZ 2003555A3 CZ 2003555 A CZ2003555 A CZ 2003555A CZ 2003555 A CZ2003555 A CZ 2003555A CZ 2003555 A3 CZ2003555 A3 CZ 2003555A3
Authority
CZ
Czechia
Prior art keywords
heteroalkyl
compound
hydrogen
dione
disease
Prior art date
Application number
CZ2003555A
Other languages
Czech (cs)
English (en)
Inventor
Leyi Gong
Andrew Grupe
Gary Allen Peltz
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CZ2003555A3 publication Critical patent/CZ2003555A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CZ2003555A 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta CZ2003555A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
CZ2003555A3 true CZ2003555A3 (en) 2004-03-17

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2003555A CZ2003555A3 (en) 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta

Country Status (31)

Country Link
US (2) US6479490B2 (https=)
EP (1) EP1307447B1 (https=)
JP (1) JP3984157B2 (https=)
KR (1) KR20030017655A (https=)
CN (1) CN1185229C (https=)
AR (1) AR033989A1 (https=)
AT (1) ATE284885T1 (https=)
AU (1) AU2001293702A1 (https=)
BR (1) BR0112965A (https=)
CA (1) CA2417277A1 (https=)
CZ (1) CZ2003555A3 (https=)
DE (1) DE60107857T2 (https=)
EC (1) ECSP034452A (https=)
ES (1) ES2233691T3 (https=)
GT (1) GT200100151A (https=)
HR (1) HRP20030030A2 (https=)
HU (1) HUP0301431A2 (https=)
IL (1) IL153851A0 (https=)
JO (1) JO2293B1 (https=)
MA (1) MA26936A1 (https=)
MX (1) MXPA03000695A (https=)
NO (1) NO20030328D0 (https=)
NZ (1) NZ523462A (https=)
PA (1) PA8523001A1 (https=)
PE (1) PE20020338A1 (https=)
PL (1) PL366701A1 (https=)
RU (1) RU2003104796A (https=)
UY (1) UY26857A1 (https=)
WO (1) WO2002010158A2 (https=)
YU (1) YU4403A (https=)
ZA (1) ZA200300216B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
EA200300442A1 (ru) * 2000-10-02 2003-10-30 Редди Ю Эс Терапьютикс, Инк. Способы и композиции для лечения воспалительных заболеваний
AU2002221810B2 (en) * 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
JP2005532982A (ja) * 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
AU2003235798A1 (en) * 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
DK1483265T3 (da) 2002-03-05 2007-03-19 Lilly Co Eli Purinderivater som kinaseinhibitorer
MXPA04008671A (es) 2002-03-08 2004-12-06 Lilly Co Eli Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
DE60323749D1 (de) 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
MXPA04012188A (es) 2002-06-05 2005-07-25 Johnson & Johnson Derivados de bisindolil-maleimida como inhibidores de cinasa.
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US20070142401A1 (en) * 2003-10-27 2007-06-21 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
EP1746886A1 (en) * 2004-05-12 2007-01-31 Bayer CropScience GmbH Plant growth regulation
US8008320B2 (en) 2004-12-08 2011-08-30 Johannes Gutenberg-Universitatis 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JP4747364B2 (ja) 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
CN102131801B (zh) * 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2614053B1 (en) * 2010-09-08 2016-03-23 Sumitomo Chemical Company Limited Method for producing pyridazinone compounds and intermediates thereof
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458B (zh) 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
EP0868195A2 (en) 1995-12-20 1998-10-07 Medical Research Council Control of protein synthesis, and screening method for agents
EP1019043A4 (en) 1996-05-07 2003-07-30 Univ Pennsylvania INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
YU4403A (sh) 2006-05-25
HK1058670A1 (en) 2004-05-28
GT200100151A (es) 2002-05-23
DE60107857T2 (de) 2005-12-08
PL366701A1 (en) 2005-02-07
NO20030328L (no) 2003-01-22
EP1307447B1 (en) 2004-12-15
ES2233691T3 (es) 2005-06-16
PE20020338A1 (es) 2002-04-23
WO2002010158A3 (en) 2002-05-16
MA26936A1 (fr) 2004-12-20
JP2004505078A (ja) 2004-02-19
EP1307447A2 (en) 2003-05-07
JO2293B1 (en) 2005-09-12
CN1185229C (zh) 2005-01-19
IL153851A0 (en) 2003-07-31
HRP20030030A2 (en) 2005-02-28
KR20030017655A (ko) 2003-03-03
UY26857A1 (es) 2002-01-31
US20020188018A1 (en) 2002-12-12
ATE284885T1 (de) 2005-01-15
ZA200300216B (en) 2004-04-08
US6479490B2 (en) 2002-11-12
WO2002010158A2 (en) 2002-02-07
MXPA03000695A (es) 2003-06-04
JP3984157B2 (ja) 2007-10-03
BR0112965A (pt) 2003-07-08
PA8523001A1 (es) 2002-10-24
DE60107857D1 (de) 2005-01-20
ECSP034452A (es) 2003-03-10
NO20030328D0 (no) 2003-01-22
AR033989A1 (es) 2004-01-21
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
CA2417277A1 (en) 2002-02-07
CN1444581A (zh) 2003-09-24
HUP0301431A2 (hu) 2003-08-28
AU2001293702A1 (en) 2002-02-13
US20020052397A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
CZ2003555A3 (en) 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
CN106536520B (zh) 芳基受体调制剂及其制备和使用方法
MX2010013920A (es) Alcoholes alquinilicos como inhibidores de cinasas.
JPWO2013018695A1 (ja) 複素環化合物
EP1689739B1 (en) Azole-based kinase inhibitors
AU2014348422B2 (en) EBNA1 inhibitors and their method of use
JP2000509719A (ja) 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用
CN101541788A (zh) 作为激酶抑制剂的化合物和组合物
CN1158283C (zh) 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
EP3027602A1 (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1465610B1 (en) Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
CN102316738A (zh) 作为激酶抑制剂的酰胺类
ES2427968T3 (es) Nuevos derivados de indol que tienen un grupo carbamoilo, un grupo ureido y un grupo oxi sustituido
EP2140862A2 (en) Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
KR20260020409A (ko) Ikzf1-4 단백질의 수준을 감소시키기 위한 치환된 옥사졸론 화합물
CN103228644B (zh) Ccr2的4-取代-环己基氨基-4-哌啶基-乙酰胺拮抗剂
FR2969611A1 (fr) Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HK40127606A (zh) 经取代的苯基恶唑酮化合物
HK1058670B (en) 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
HK1065484A (en) Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
HK1133202A (en) Use of gal 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
FR2969608A1 (fr) Nouveaux derives de (5-halo-6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)